We are live on ! Find out more
KDNY

Chinook Therapeutics, Inc. Common Stock

Delisted

KDNY was delisted on the 10th of August, 2023.

87 hedge funds and large institutions have $275M invested in Chinook Therapeutics, Inc. Common Stock in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 33 increasing their positions, 23 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more call options, than puts

Call options by funds: $797K | Put options by funds: $398K

43% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 23

5% less funds holding

Funds holding: 9287 (-5)

8% less capital invested

Capital invested by funds: $297M → $275M (-$22.3M)

26% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 19

Holders
87
Holders Change
-5
Holders Change %
-5.43%
% of All Funds
2.17%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
14
Increased
33
Reduced
23
Closed
19
Calls
$797K
Puts
$398K
Net Calls
+$399K
Net Calls Change
-$22K

KDNY Hedge Fund Activity: Q4 2016 in Review

87 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q4 2016, worth a combined $275M — down 7.5% from $297M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of KDNY and 14 opened new positions — a net loss of 5 holders — while 23 trimmed existing stakes and 33 added.

The largest buyer was Wellington Management Group, adding an estimated $28.5M. The largest seller was Fidelity Investments, cutting an estimated $27.3M.

  • 87 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q4 2016, down from 92 in Q3 2016.
  • Funds reported $275M of Chinook Therapeutics, Inc. Common Stock stock for Q4 2016, down 7.5% quarter-over-quarter.
  • 14 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q4 2016 and 19 closed out, a net change of -5 holders.
  • The largest Chinook Therapeutics, Inc. Common Stock buyer in Q4 2016 was Wellington Management Group, an estimated $28.5M added.
  • The largest Chinook Therapeutics, Inc. Common Stock seller in Q4 2016 was Fidelity Investments, an estimated $27.3M sold.

Based on aggregated 13F filings for Q4 2016.